Jan Philipp Bewersdorf, MD
he/him/his
Assistant ProfessorDownloadHi-Res Photo
Cards
Are You a Patient?
View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.
View Doctor ProfileContact Info
Hematology
333 Cedar Street, PO Box 208028
New Haven, CT 06520
United States
About
Titles
Assistant Professor
Biography
Dr. Jan Philipp Bewersdorf is an Assistant Professor of Medicine (Hematology) at Yale University. Following medical school training in Germany, he completed his Internal Medicine training at Yale - New Haven Hospital. After completion of residency, Dr. Bewersdorf pursued his fellowship in Hematology and Medical Oncology at Memorial Sloan Kettering Cancer Center in New York before joining the faculty at Yale in July 2024. Dr. Bewersdorf is board-certified in Internal Medicine, Medical Oncology and Hematology.
His career as a clinician-scientist has been dedicated to myeloid malignancies spanning from myeloproliferative neoplasms to myelodysplastic syndromes and acute myeloid leukemia. Dr. Bewersdorf's work aims to combine basic and translational research with clinical and outcomes research to study those disorders from multiple angles. Inspired by the privilege of taking care of patients with myeloid neoplasms, he strives to advance patient care by conducting innovative clinical trials with a strong correlative component in collaboration with laboratory-based colleagues. He has developed and co-led several early phase clinical trials in myeloid malignancies and his research efforts have led to over 130 peer-reviewed publications to date including first-author publications in Lancet, Blood, Leukemia, and Lancet Haematology.
Dr. Bewersdorf has received several prestigious awards including the Edwards P. Evans Young Investigator Award, the Mortimer Lacher Fellowship from the Lymphoma Foundation, and multiple other achievement awards. He also serves on the editorial board and is a reviewer of several important hematology and oncology journals.
Appointments
Hematology
Assistant ProfessorPrimary
Other Departments & Organizations
- Hematology
- Yale Medicine
Education & Training
- Fellowship
- Memorial Sloan Kettering Cancer Center (2024)
- Chief Fellow
- Memorial Sloan Kettering Cancer Center (2024)
- Resident
- Yale - New Haven Hospital (2021)
- Resident
- Ludwig-Maximilians-University Munich (2018)
- MD
- Ludwig-Maximilians-University Munich (2017)
Research
Overview
Medical Research Interests
Clinical Trial; Immune System; Leukemia; Leukemia, Myeloid; Myelodysplastic Syndromes
Public Health Interests
Health Economics
ORCID
0000-0003-3352-0902
Research at a Glance
Yale Co-Authors
Frequent collaborators of Jan Philipp Bewersdorf's published research.
Publications Timeline
A big-picture view of Jan Philipp Bewersdorf's research output by year.
Research Interests
Research topics Jan Philipp Bewersdorf is interested in exploring.
Amer Zeidan, MBBS
Rory Shallis, MD
Nikolai Podoltsev, MD, PhD
Scott Huntington, MD, MPH, MSc
Rong Wang, PhD
Stephanie Halene, MD, Dr Med
180Publications
2,290Citations
Myelodysplastic Syndromes
Leukemia
Leukemia, Myeloid
Publications
2024
Cost-effectiveness of Enasidenib versus conventional care for older patients with IDH2-mutant refractory/relapsed AML
Alhajahjeh A, Patel K, Shallis R, Podoltsev N, Kewan T, Stempel J, Mendez L, Huntington S, Stahl M, Goshua G, Bewersdorf J, Zeidan A. Cost-effectiveness of Enasidenib versus conventional care for older patients with IDH2-mutant refractory/relapsed AML. Leukemia & Lymphoma 2024, ahead-of-print: 1-9. PMID: 39560957, DOI: 10.1080/10428194.2024.2426073.Peer-Reviewed Original ResearchAltmetricConceptsConventional care regimensOlder patientsTreatment of older patientsIDH2 inhibitor enasidenibIncremental cost-effectiveness ratioCost-effectiveness ratioProbabilistic sensitivity analysesR/R AMLRefractory/relapsed AMLEvent-freeCost-effective treatmentEnasidenibCare regimensAMLPatientsCost-effectiveIncremental costLife yearsConventional careR/RIncremental effectSurvivalTreatmentGlobal Disparities in the Characteristics and Outcomes of Leukemia Clinical Trials: A Cross-Sectional Study of the ClinicalTrials.gov Database.
Alhajahjeh A, Rotter L, Stempel J, Grimshaw A, Bewersdorf J, Blaha O, Kewan T, Podoltsev N, Shallis R, Mendez L, Stahl M, Zeidan A. Global Disparities in the Characteristics and Outcomes of Leukemia Clinical Trials: A Cross-Sectional Study of the ClinicalTrials.gov Database. JCO Global Oncology 2024, 10: e2400316. PMID: 39621951, DOI: 10.1200/go-24-00316.Peer-Reviewed Original ResearchMeSH Keywords and ConceptsFuture directions in myelodysplastic syndromes/neoplasms and acute myeloid leukaemia classification: from blast counts to biology
Della Porta M, Bewersdorf J, Wang Y, Hasserjian R. Future directions in myelodysplastic syndromes/neoplasms and acute myeloid leukaemia classification: from blast counts to biology. Histopathology 2024 PMID: 39450427, DOI: 10.1111/his.15353.Peer-Reviewed Original ResearchAltmetricConceptsAcute myeloid leukemiaIntegration of genomic dataGenomic informationGenomic dataPresence of SF3B1 mutationsDisease entityMethylation profilesAML classificationRecurrent genetic abnormalitiesHaematopoietic cell proliferationPercentage of myeloblastsGene expressionGenetic featuresMultiple diagnostic modalitiesPatient risk stratificationSF3B1 mutationsBlast countDisease pathogenesisGenetic abnormalitiesCell proliferationTP53 abnormalitiesDiagnostic modalitiesMyeloid leukemiaBone marrowPatient cohortAnalyzing determinants of premature trial discontinuation in leukemia clinical trials
Rotter L, Alhajahjeh A, Stempel J, Grimshaw A, Bewersdorf J, Blaha O, Kewan T, Podoltsev N, Shallis R, Mendez L, Stahl M, Zeidan A. Analyzing determinants of premature trial discontinuation in leukemia clinical trials. Leukemia & Lymphoma 2024, ahead-of-print: 1-9. PMID: 39440622, DOI: 10.1080/10428194.2024.2416565.Peer-Reviewed Original ResearchAltmetricConceptsClinical trialsSlow accrualLeukemia trialsEarly-phase trialsNon-randomized trialsAcademic-sponsored trialsImprove patient outcomesLeukemia clinical trialsSingle-centerTrial discontinuationSponsored trialsSmall trialsLeukemiaEarly terminationPatient outcomesLate-phaseIndependent reviewersTermination ratesComprehensive searchTrialsTargeted therapies for myelodysplastic syndromes/neoplasms (MDS): current landscape and future directions
Bidikian A, Bewersdorf J, Shallis R, Getz T, Stempel J, Kewan T, Stahl M, Zeidan A. Targeted therapies for myelodysplastic syndromes/neoplasms (MDS): current landscape and future directions. Expert Review Of Anticancer Therapy 2024, 24: 1131-1146. PMID: 39367718, DOI: 10.1080/14737140.2024.2414071.Peer-Reviewed Original ResearchAltmetricConceptsErythropoiesis-stimulating agentsTargeted therapyLR-MDSHR-MDSHypoxia-inducible factorAllogeneic hematopoietic stem cell transplantationLandscape of targeted therapiesHematopoietic stem cell transplantationHeterogeneous group of hematologic malignanciesGroup of hematologic malignanciesMolecular prognostic toolsDuration of responseStem cell transplantationTrial designClinical trial designHypomethylating agentsCell transplantationHematologic malignanciesImprove patient outcomesRNA splicing machineryImmune evasionPrognostic toolTGF-betaTherapyEffective treatmentPacritinib Response Is Associated With Overall Survival in Myelofibrosis: PERSIST‐2 Landmark Analysis of Survival
Ajufo H, Bewersdorf J, Harrison C, Palandri F, Mascarenhas J, Palmer J, Gerds A, Kiladjian J, Buckley S, Derkach A, Roman‐Torres K, Rampal R. Pacritinib Response Is Associated With Overall Survival in Myelofibrosis: PERSIST‐2 Landmark Analysis of Survival. European Journal Of Haematology 2024 PMID: 39400386, DOI: 10.1111/ejh.14321.Peer-Reviewed Original ResearchAltmetricConceptsSpleen volume reductionOverall survivalOS benefitNon-respondersAssociated with improved OSPatients treated with ruxolitinibAssociated with overall survivalAssociated with significant OS benefitImproved overall survivalSignificant OS benefitPERSIST-2Analysis of survivalUnique survival advantagesInhibitor of Janus kinaseJanus kinaseOS curvesRetrospective analysisSurvival advantageMyelofibrosisPacritinibPatientsRuxolitinibPlateletThrombocytopeniaVolume reductionData-driven, harmonised classification system for myelodysplastic syndromes: a consensus paper from the International Consortium for Myelodysplastic Syndromes
Komrokji R, Lanino L, Ball S, Bewersdorf J, Marchetti M, Maggioni G, Travaglino E, Al Ali N, Fenaux P, Platzbecker U, Santini V, Diez-Campelo M, Singh A, Jain A, Aguirre L, Tinsley-Vance S, Schwabkey Z, Chan O, Xie Z, Brunner A, Kuykendall A, Bennett J, Buckstein R, Bejar R, Carraway H, DeZern A, Griffiths E, Halene S, Hasserjian R, Lancet J, List A, Loghavi S, Odenike O, Padron E, Patnaik M, Roboz G, Stahl M, Sekeres M, Steensma D, Savona M, Taylor J, Xu M, Sweet K, Sallman D, Nimer S, Hourigan C, Wei A, Sauta E, D’Amico S, Asti G, Castellani G, Delleani M, Campagna A, Borate U, Sanz G, Efficace F, Gore S, Kim T, Daver N, Garcia-Manero G, Rozman M, Orfao A, Wang A, Foucar M, Germing U, Haferlach T, Scheinberg P, Miyazaki Y, Iastrebner M, Kulasekararaj A, Cluzeau T, Kordasti S, van de Loosdrecht A, Ades L, Zeidan A, Della Porta M, Syndromes I. Data-driven, harmonised classification system for myelodysplastic syndromes: a consensus paper from the International Consortium for Myelodysplastic Syndromes. The Lancet Haematology 2024, 11: e862-e872. PMID: 39393368, DOI: 10.1016/s2352-3026(24)00251-5.Peer-Reviewed Original ResearchCitationsAltmetricConceptsGenomic featuresData-driven approachTP53 inactivationGenomic heterogeneityEntity labelsGenetic featuresDel(7q)/-7Myelodysplastic syndromeGenomic profilingData scientistsMutated SF3B1Cluster assignmentComplex karyotypeRUNX1 mutationsModified Delphi consensus processDel(5qIsolated del(5qAcute myeloid leukemiaData-drivenDelphi consensus processMarrow blastsContemporary Approach to the Diagnosis and Classification of Myelodysplastic Neoplasms/Syndromes—Recommendations From the International Consortium for Myelodysplastic Neoplasms/Syndromes (MDS [icMDS])
Aakash F, Gisriel S, Zeidan A, Bennett J, Bejar R, Bewersdorf J, Borate U, Boultwood J, Brunner A, Buckstein R, Carraway H, Churpek J, Daver N, DeZern A, Efficace F, Fenaux P, Figueroa M, Garcia-Manero G, Gore S, Greenberg P, Griffiths E, Halene S, Hourigan C, Kim T, Kim N, Komrokji R, Kutchroo V, List A, Little R, Majeti R, Nazha A, Nimer S, Odenike O, Padron E, Patnaik M, Platzbecker U, Della Porta M, Roboz G, Sallman D, Santini V, Sanz G, Savona M, Sekeres M, Stahl M, Starczynowski D, Steensma D, Taylor J, Abdel-Wahab O, Wei A, Xie Z, Xu M, Hasserjian R, Loghavi S. Contemporary Approach to the Diagnosis and Classification of Myelodysplastic Neoplasms/Syndromes—Recommendations From the International Consortium for Myelodysplastic Neoplasms/Syndromes (MDS [icMDS]). Modern Pathology 2024, 37: 100615. PMID: 39322118, DOI: 10.1016/j.modpat.2024.100615.Peer-Reviewed Original ResearchAltmetricConceptsIntensive induction chemotherapy vs hypomethylating agents in combination with venetoclax in NPM1-mutant AML
Bewersdorf J, Shimony S, Shallis R, Liu Y, Berton G, Schaefer E, Zeidan A, Goldberg A, Stein E, Marcucci G, Bystrom R, Lindsley R, Chen E, Perez J, Stein A, Pullarkat V, Aldoss I, DeAngelo D, Neuberg D, Stone R, Garciaz S, Ball B, Stahl M. Intensive induction chemotherapy vs hypomethylating agents in combination with venetoclax in NPM1-mutant AML. Blood Advances 2024, 8: 4845-4855. PMID: 38941537, PMCID: PMC11416634, DOI: 10.1182/bloodadvances.2024012858.Peer-Reviewed Original ResearchCitationsAltmetricConceptsIntensive induction chemotherapyAcute myeloid leukemiaNPM1-Mutant Acute Myeloid LeukemiaInduction chemotherapyHypomethylating agentsMulticenter retrospective cohort study of patientsPatients treated with ICAllogeneic stem cell transplantationRetrospective cohort study of patientsMulticenter retrospective cohort studyCohort study of patientsComposite complete remissionStem cell transplantationYears-oldFLT3-ITD mutationStudy of patientsStandard of careNormal cytogeneticsComplete remissionCell transplantationNPM1 mutationsMyeloid leukemiaFLT3-ITDYounger patientsOlder patientsBeyond HMAs: Novel targets and therapeutic approaches
Getz T, Bewersdorf J, Kewan T, Stempel J, Bidikian A, Shallis R, Stahl M, Zeidan A. Beyond HMAs: Novel targets and therapeutic approaches. Seminars In Hematology 2024 PMID: 39389839, DOI: 10.1053/j.seminhematol.2024.08.001.Peer-Reviewed Original ResearchCitationsConceptsAcute myeloid leukemiaDelays progression to acute myeloid leukemiaHeterogeneous group of clonal hematopoietic disordersGroup of clonal hematopoietic disordersMolecular International Prognostic Scoring SystemRandomized phase 3 clinical trialProgression to acute myeloid leukemiaInternational Prognostic Scoring SystemLower-risk MDS patientsRisk stratification of patientsPhase 3 clinical trialsCombination of azacitidineHypomethylating agent combinationsCurrent treatment landscapeFirst line therapyPrognostic Scoring SystemBiomarker-directed therapiesClonal hematopoietic disordersLack of therapeutic agentsStratification of patientsEarly phase trialsErythropoiesis stimulating agentsTreated with therapiesVariable clinical featuresStandard of care
Clinical Trials
Current Trials
A Randomized Phase II Study of Venetoclax and HMA-Based Therapies for the Treatment of Older and Unfit Adults With Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia (AML): A MyeloMATCH Treatment Trial
HIC ID2000036670RolePrincipal InvestigatorPrimary Completion Date10/31/2025Recruiting ParticipantsMYELOMATCH: A Screening Study to Assign People with Myeloid Cancer to a Treatment Study or Standard of Care Treatment within myeloMATCH (MyeloMATCH Screening Trial)
HIC ID2000036669RolePrincipal InvestigatorPrimary Completion Date05/15/2029Recruiting ParticipantsA Randomized, Double-blind, Placebo-controlled, Multicenter Phase 2 Study of AK117/Placebo in Combination With Azacitidine in Patients With Newly Diagnosed Higher-risk Myelodysplastic Syndromes
HIC ID2000036615RoleSub InvestigatorPrimary Completion Date01/31/2026Recruiting ParticipantsVenetoclax in Combination with ASTX727 for the Treatment of Chronic Myelomonocytic Leukemia and Other Myelodysplastic Syndromes/Myeloproliferative Neoplasms
HIC ID2000035366RolePrincipal InvestigatorPrimary Completion Date08/31/2025Recruiting ParticipantsA Randomized Phase II Study Comparing Inotuzumab Plus Chemotherapy Versus Standard Chemotherapy in Older Adults With Philadelphia-Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia
HIC ID2000034665RoleSub InvestigatorPrimary Completion Date05/31/2028Recruiting Participants
Academic Achievements & Community Involvement
activity Expert Reviews of Hematology
Journal ServiceReviewerDetails2019 - Presentactivity Cancer
Journal ServiceReviewerDetails2020 - Presentactivity Leukemia
Journal ServiceReviewerDetails2021 - Presentactivity Clinical Cancer Research
Journal ServiceReviewerDetails2022 - Presentactivity Blood Advances
Journal ServiceReviewerDetails2024 - Present
Clinical Care
Overview
Clinical Specialties
Hematology; Hematologic Oncology; Leukemia & Lymphoma
Fact Sheets
Diagnosing Leukemia
Learn More on Yale MedicineCytogenic Studies for Leukemia Diagnosis
Learn More on Yale MedicineLeukemia in Children
Learn More on Yale Medicine
Board Certifications
Hematology (Internal Medicine)
- Certification Organization
- AB of Internal Medicine
- Original Certification Date
- 2024
Medical Oncology
- Certification Organization
- AB of Internal Medicine
- Original Certification Date
- 2023
Internal Medicine
- Certification Organization
- AB of Internal Medicine
- Original Certification Date
- 2021
Are You a Patient?
View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.
View Doctor ProfileNews
News
- August 14, 2024
Welcome New Staff, Faculty, Fellows, Postgrads & Postdocs (August 2024)
- July 17, 2024
Hematologist, Dr. Jan Bewersdorf, Joins Smilow Cancer Hospital
- March 10, 2021
Discoveries & Impact (March 2021)
- October 14, 2020
Discoveries & Impact (October 2020)
Get In Touch
Contacts
Appointment Number
Mailing Address
Hematology
333 Cedar Street, PO Box 208028
New Haven, CT 06520
United States
Administrative Support
Locations
Patient Care Locations
Are You a Patient? View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.